Tactile Systems Technology INC: insider trades · United States · SEC (Form 4)

About Tactile Systems Technology INC

Tactile Systems Technology, Inc. is a U.S.-based medical technology company listed on the Nasdaq under the ticker TCMD in the United States. The company develops and commercializes at-home medical devices for underserved chronic conditions, with a strategy centered on reimbursement-supported therapies, clinician referrals, and direct patient engagement. Originally incorporated in Minnesota in 1995, the company later reincorporated in Delaware and operates today from its headquarters in Minneapolis, Minnesota. It began doing business as “Tactile Medical” in 2013. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1027838/000155837025001096/tcmd-20241231x10k.htm)) Tactile Medical’s core business is organized around two main therapeutic franchises. The first is pneumatic compression therapy for lymphedema and chronic venous insufficiency, marketed through the Flexitouch Plus, Entre Plus, and Nimbl systems. The second is airway clearance therapy, led by AffloVest, a portable high-frequency chest wall oscillation vest used for certain chronic respiratory disorders. In practical terms, the company sits at the intersection of medtech, chronic disease management, and home-based care. Its products are designed to be used outside the hospital, which is a meaningful differentiator in an environment where payers and policymakers increasingly favor lower-cost, home-delivered treatment pathways. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1027838/000155837025001096/tcmd-20241231x10k.htm)) From a competitive standpoint, Tactile Medical emphasizes clinically differentiated, proprietary devices rather than commodity hardware. Flexitouch Plus is its advanced programmable platform, designed for multiple body areas and supported by Bluetooth-enabled data reporting through the Kylee companion app. Entre Plus addresses patients who need a simpler pump or who have not yet qualified for advanced-device reimbursement. Nimbl is the next-generation platform, cleared by the FDA in 2024 and commercially available in the United States, with broader launch activity in 2025. The company also notes that its in-network or contracted payer coverage extends across more than 275 million lives in the United States, underscoring the importance of reimbursement access in its commercial model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1027838/000155837025001096/tcmd-20241231x10k.htm)) Geographically, the business is overwhelmingly U.S.-centric. Revenue is derived primarily from sales and rentals to patients in the United States, as well as sales to durable medical equipment providers for AffloVest. The company uses a direct-to-patient and direct-to-provider model for its lymphedema portfolio, while respiratory products are distributed through DME channels. This creates a hybrid go-to-market structure that combines clinical education, insurance processing, and patient onboarding. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1027838/000155837025001096/tcmd-20241231x10k.htm)) Recent developments have been constructive. In February 2025, Tactile Medical expanded the commercial launch of Nimbl to include lower-extremity lymphedema patients in the U.S. In its February 2026 full-year earnings release, the company reported 2025 revenue growth of 12% year over year and highlighted improved gross margin and profitability metrics. It also announced a second share repurchase program in late 2025, indicating greater capital return discipline. For investors, TCMD remains a niche U.S. medtech story with exposure to reimbursement trends, product adoption, and execution on newer platforms. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/02/04/3020263/0/en/Tactile-Medical-Expands-Launch-of-Nimbl-to-Include-Patients-with-Lower-Extremity-Lymphedema.html))